Chargement en cours...
Future Research Priorities for Morbidity Control of Lymphedema
BACKGROUND: Innovation in the treatment of lower extremity lymphedema has received low priority from the governments and pharmaceutical industry. Advancing lymphedema is irreversible and initiates fibrosis in the dermis, reactive changes in the epidermis and subcutis. Most medical treatments offered...
Enregistré dans:
| Publié dans: | Indian J Dermatol |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Medknow Publications & Media Pvt Ltd
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5286751/ https://ncbi.nlm.nih.gov/pubmed/28216723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0019-5154.198039 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|